BCV
VKTX icon

Banque Cantonale Vaudoise’s Viking Therapeutics VKTX Stock Holding History

Banque Cantonale Vaudoise’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$149 Sell
3,831
-50
-1% -$1.61K ﹤0.01% 669
2026
Q1 		$126K Hold
3,881
– – ﹤0.01% 693
2025
Q4 		$136K Buy
3,881
+129
+3% +$4.57K ﹤0.01% 598
2025
Q3 		$98K Buy
3,752
+536
+17% +$16K ﹤0.01% 621
2025
Q2 		$85K Hold
3,216
– – ﹤0.01% 607
2025
Q1 		$77K Buy
+3,216
New +$102K ﹤0.01% 654

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Banque Cantonale Vaudoise's VKTX Position: Q2 2026 in Review

Banque Cantonale Vaudoise reduced its Viking Therapeutics (VKTX) stake by 1.3% in Q2 2026, selling an estimated $1.61K and leaving 3,831 shares worth $149. The position accounts for ﹤0.01% of the portfolio, ranked #669.

Banque Cantonale Vaudoise first reported a position in VKTX in Q1 2025 and has held it in 6 quarters since. The position peaked at $136K in Q4 2025. 436 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Banque Cantonale Vaudoise held 3,831 shares of Viking Therapeutics worth $149 as of Q2 2026.
  • Banque Cantonale Vaudoise sold 50 Viking Therapeutics shares in Q2 2026, an estimated $1.61K.
  • Viking Therapeutics made up ﹤0.01% of Banque Cantonale Vaudoise's portfolio in Q2 2026, its #669 holding.
  • Banque Cantonale Vaudoise first reported a position in Viking Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • Banque Cantonale Vaudoise's Viking Therapeutics position peaked at $136K in Q4 2025.
  • 436 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Banque Cantonale Vaudoise's 13F filing for Q2 2026, filed 31 Jul 2026.